FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:1394-1396 October 1, 2009 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Moss, A. J. PubMed Citation

Cardiac-resynchronization therapy (CRT) received Food and Drug Administration approval for use in selected patients with left ventricular systolic dysfunction in 2001. Since that time, CRT has been embraced as a recommended approach to achieve meaningful clinical improvement in patients who have heart failure with a reduced left ventricular ejection fraction (LVEF) and who continue to have symptoms despite optimal medical therapy.¹ A number of pivotal randomized trials and scores of additional safety and effectiveness trials have consistently shown that CRT improves the LVEF, quality of life, and functional status in symptomatic patients with an LVEF of less than 35% and . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Cardiovascular Division, University of Pennsylvania School of Medicine, Philadelphia.

This article (10.1056/NEJMe0907335) was published on September 1, 2009, at NEJM.org.

This article has been cited by other articles:

• Francis, G. S., Wilson Tang, W.H. (2009). Early Cardiac Resynchronization Therapy and Reverse Remodeling in Patients With Mild Heart Failure: Is It Time?. Circulation 120: 1845-1846 [Full Text]